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which will allow us to devise 'guidelines for the safe use of
radiation in everyday life'. This laudable intention has, how-
ever, not been achieved. The major health hazards of low
dose radiation are cancer induction, genetic damage and to a
lesser extent CNS damage following irradiation of the em-
bryo and foetus. But these receive scant attention, with just
two pages each on the genetic and foetal effects and only
nine pages on carcinogenesis.
The perfect textbook has never been written; but a sub-
stantive criticism of this basic book on radiobiology must be
that the balance of information is awry. There is too much
stress on cellular effects, too little stress on DNA damage
and much too little on the societally important low level
radiation health effects of carcinogenesis, teratogenesis and
genetic damage.
J.E. Coggle
Neoadjuvant Chemotherapy in Invasive Bladder Cancer
Edited by Ted A.W. Splinter and Howard I. Scher, New
York: Willey-Liss, 1990, 241 pp. £57.50.
It is now 7 years since the demonstration by Carmichael in
1983 that methotrexate combined with cisplatin produced
durable complete remission in a small proportion of patients
with measurable metastatic bladder cancer. Since this time
the four drug combination developed by the Memorial Hos-
pital has become the most widely used regimen for
combination, because of suggestion that there was a higher
complete response rate using this regimen in patients with
metastases. As a consequence of these observations, today
the majority of centres involved in research in bladder cancer
treatment have now taken this observation and use platinum
containing combination instead of radiation as their standard
adjuvant regimen for the treatment of invasive bladder
tumours without metastases. This book which is the pro-
ceedings of a workshop held in San Francisco 18 months ago
proves to be an invaluable resource of reference to the effect
of this change in policy, though sadly it raises as many
questions as it answers.
After a series of review papers about chemotherapy, radia-
tion, pathology of tumours after treatment and trial design,
there are five papers about randomised trials and nine about
phase 2 studies from 12 different countries and six chapters
about assessing response to treatment. Sadly in the critical
area of the randomised trial none have advanced to the stage
of having any information on response or survival. Despite
the fact that it is going to be at least another 2-3 years
before information will emerge from the randomised trials,
the maturation of the phase 2 studies which led to the initial
enthusiasm for this approach and the increase in number of
other authors who have got phase 2 data, does make it easier
to get a feel that the likely benefits are more likely to be
closer to those seen from using chemotherapy to treat
primary head and neck cancer than from that gained from
using it as adjuvant for breast cancer.
The critical information is that provided in the first
chapter by Howard Scher who has done an excellent work in
summarising the literature and the contributions from
participants. This shows clearly that the proportion of
patients with previously untreated primary bladder cancer
achieving complete remission while only being 11% for single
agent platinum, was more than 20% for all platinum based
combinations. However there was no difference between the
two drug combinations methotrexate cisplatin (33%) and the
four drug Memorial M-VAC regimen (32%). Though there
was mention of one small trial where the two have been
compared, this is obviously an important area that will need
focusing on in the future, particularly as this complete remis-
sion rate is lower than that reported by many authors who
have used the considerably less toxic radiation as primary
treatment.
A final area of considerable controversy, which is the
subject of one chapter by Reg Hall, is the issue of whether
transurethral resection of tumour (TURT) should be used to
reduce tumour bulk prior to chemotherapy treatment. Sadly
it is rather difficult to assess his extremely important data as
the text says that 70-80% of his patients remain tumour free
while the data presented in the table shows that at 2 years
only 50% have a bladder free of tumour following TURT
and combination chemotherapy which is worse than he
achieved using single agent methotrexate alone after TURT
(57% at 3 years). As none of the other authors give any
information about how much resection of tumour they did
prior to treatment, it is clear that more assessment of this
variable is required. Given the anxiety raised from studies in
prostate cancer which suggest that there may be increased
intravascular and lymphatic dissemination after transurethral
resection, it would be important to exclude such as effect
happening in bladder cancer patients who have TURT.
The final section of the book on assessing response is very
useful in its own right, because it provides important prog-
nostic information (in particular the influence of tumour size
and response to treatment on survival) as well as publishing
two of the first papers that have actually gone to the trouble
of computing tumour volume before and after treatment,
though the figure in Sager's paper showing shrinkage of what
is labelled as the uterus after chemotherapy does emphasise
the limits of the technology at present.
I am sure that there can be little doubt that this book will
be an important reference for the future, though its message
to me is that we still have far to go if we are to improve on
the figure of 30% 5-year survival for T3 bladder cancer
which has been with us since the advent of megavoltage
radiotherapy.
R.T.D. Oliver
Current Genitourinary Cancer Surgery
Edited by E. Crawford and S. Das, London: Lea & Febiger,
1990, 249 pp. £87.35.
Professor Crawford and Dr Das have persuaded 81 surgeons
and physicians to contribute to this edition of Genitourinary
Cancer Surgery. No significant tumour or tumour-type has
been ignored and all are considered in a most practical way
which allows both the trainee and the expert to feel at home
with, and to benefit from, the views expressed. Each major
section has an overview which clearly sets out the accepted
basic information, draws attention to contentious issues and
highlights some of the problems which both physician and
surgeon must face on a daily basis. It is a book for surgeons
by surgeons and very properly gives over the majority of its
test to a consideration of the indications for, and alternatives
in techniques of, urological cancer surgery. Despite the
number of authors, the editing has produced a marvellously
uniform text of great clarity with a wealth of illustrations of
the very highest quality drawing attention to details of
critical surgical importance.
The editors have cast their net widely and have incorpor-
ated every relevant surgical advance without endeavouring to
force the acceptance of any particular option considered.
The reader from Europe will notice the American usage of
English and will be aware from such statements as 'approxi-
mately 47,100 new cases of bladder carcinoma will be diag-
nosed this year'; and '. . . cystectomy remains the therapeutic
choice for patients with invasive bladder cancer,' that this
book is primarily written for Americans. The case for surgi-